European heart journal. Acute cardiovascular care · 2026
A novel device for temporary cardiac stimulation using permanent pacemaker generators and active-fixation leads: the TEMPACE multicentre prospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vicente-Miralles Raimundo, Rivas-Gándara Nuria, Jordán Marchite Pablo, Adeliño Raquel, Carmona María Ángeles, Díaz Barranco Mónica, Ibañez Criado Alicia Ascensión, Ruiz Nodar Juan Miguel, Ajo Ferrer María, García-Fernández Amaya, Bertomeu-Gonzalez Vicente, Martínez Martínez Juan Gabriel
Аннотация
AIMS: This study aims to determine the safety and effectiveness of the KronoSafe® permanent pacemaker adapter for temporary cardiac pacing (TCP) with active-fixation leads (TCPAFLs).
METHODS AND RESULTS: This was a multicentre, prospective, descriptive clinical investigation involving a medical device (ClinicalTrials.gov identifier: NCT05351658). Between January 2023 and December 2024, all consecutive patients who underwent implantation of a temporary active-fixation pacemaker were included. The devices were secured using the KronoSafe® adapter throughout the period of use. Complications during TCPAFL were recorded, and R-wave sensing, lead impedance, and pacing threshold were determined every 48 h. Thirty patients (10 with atrioventricular block, nine TAVI, five alcohol septal ablations, two slow atrial fibrillations, two bradycardia-tachycardia syndrome, and two pacemaker infections) who required TCP were included. Two centres participated in the study. The mean duration of TCP was 7.8 days (maximum 22 days), with 79.2% of the time spent in the cardiology ward. One complication (3%) was recorded, due to accidental traction of the system associated with an episode of agitation.
CONCLUSION: Temporary cardiac pacing with active-fixation leads using the KronoSafe® adapter is safe and effective, and its use can be extended outside the intensive care unit.
METHODS AND RESULTS: This was a multicentre, prospective, descriptive clinical investigation involving a medical device (ClinicalTrials.gov identifier: NCT05351658). Between January 2023 and December 2024, all consecutive patients who underwent implantation of a temporary active-fixation pacemaker were included. The devices were secured using the KronoSafe® adapter throughout the period of use. Complications during TCPAFL were recorded, and R-wave sensing, lead impedance, and pacing threshold were determined every 48 h. Thirty patients (10 with atrioventricular block, nine TAVI, five alcohol septal ablations, two slow atrial fibrillations, two bradycardia-tachycardia syndrome, and two pacemaker infections) who required TCP were included. Two centres participated in the study. The mean duration of TCP was 7.8 days (maximum 22 days), with 79.2% of the time spent in the cardiology ward. One complication (3%) was recorded, due to accidental traction of the system associated with an episode of agitation.
CONCLUSION: Temporary cardiac pacing with active-fixation leads using the KronoSafe® adapter is safe and effective, and its use can be extended outside the intensive care unit.